维思通治疗青少年分裂症对照研究

A Study of Risperidone in the Treatment of Adolescent Schizophrenia.

目的探讨维思通治疗青少年分裂症患者的安全性。方法依据中国精神障碍分类与诊断标准第3版(CCMD一3)选择样本,其中19例患者接受维思通治疗,剂量在3.38mg±0.65mg/日,由其父母签订治疗同意书,为研究组:18例患者接受舒必利治疗,剂量在702.78mg±45.10mg/日,为对照组,均治疗8周。入组患者治疗前后每两周检查血常规、尿常规、血糖、血尿素氮、肝功能、心电图、脑电图。疗前疗后分别测查HAS(汉密尔顿焦虑量表)、HDS(汉密尔顿抑郁量表)、BPRS(简明精神病症状评定量表),TESS(副作用症状量表)评定疗效和副反应。结果疗前疗后研究组与对照组HAS、HDS、BPRS和TESS量表分数差异均无显著性(P均>0.05);研究组与对照组治疗后HAS、HDS、BPRS量表分数均较疗前显著下降(P均<0.05);各种辅助检查结果也无明显差异。结论维思通治疗青少年分裂症患者与舒必利同样有效,且安全性相同,甚至很少有副反应。

Objective To study the efficacy and side effect of Ris pe ridone in the treatment of adolescent schizophrenia.Methods Acco rding to CCMD-3 select all samples 19 patients were treated with Risperidone,th e dosage is 3.38±0.65mg per day study group;19 patients were treated with Sulpi ride,the dosage is 702.28±45.10mg per day in contrast group before and after tr eatment,all patients were examined by BRT,URT,BGLU,BUN,Hepatic function,ECG,EEG,every two week,and the whole patients were assessed with HAS,HDS,BPRS and TESS. Results There were no significant difference in the score of HAS, HDS,BPRS,TESS and various kind sauxiliary examination between the study group an d contrast group.There were significant difference in the score of HAS,HDS,BPRS after and befor treatment between the two groups.Conclusion Risp eridone is as effective and safe anti-psychotics as sulpiride is,even seldom si de effective,in the treatment of adolescent schizophrenia.